A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)

A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)
Recruiting
18 years - 100 years
All
Phase 2
50 participants needed
1 Location

Brief description of study

Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This study is being done to see whether a new medication, called CXA-10, can reduce the amount of protein in the urine and maintain stable kidney function in patients with primary FSGS. CXA-10 is an investigational medication which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary FSGS. The pharmaceutical company sponsoring this study is Complexa, inc.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: FSGS,Primary Focal Segmental Glomerulosclerosis,
  • Age: 18 years - 100 years
  • Gender: All


Updated on 24 Apr 2024. Study ID: TX6057

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.